Evaxion Biotech AS

EVAX

Company Profile

  • Business description

    Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.

  • Contact

    Dr. Neergaards Vej 5f
    Hoersholm2970
    DNK

    T: +45 31319753

    E: [email protected]

    https://www.evaxion.ai

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    46

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,462.6040.900.49%
CAC 407,743.7549.310.64%
DAX 4023,499.32146.630.63%
Dow JONES (US)41,249.38119.07-0.29%
FTSE 1008,554.8023.190.27%
HKSE22,867.7491.820.40%
NASDAQ17,928.920.780.00%
Nikkei 22537,503.33574.701.56%
NZX 50 Index12,605.07138.041.11%
S&P 5005,659.914.03-0.07%
S&P/ASX 2008,231.2039.500.48%
SSE Composite Index3,342.0010.00-0.30%

Market Movers